Accueil・Liste d'Actions・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Ouvert

SecteurSoins de santé

258.55 9.98

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

231.82

Max

263.86

Chiffres clés
By Trading Economics
Revenu	262M -15M
Ventes	1.6M 996M
BPA	2.06
Marge bénéficiaire	-1.486
Employés	18,300
EBITDA	-135M 64M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	-1.67% downside

Dividendes
By Acuity
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.8B 11B
Ouverture précédente	248.57
Clôture précédente	258.55

Sentiment de l'Actualité

By Acuity

10%

90%

14 / 340 Classement par Healthcare

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2026, 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

3 août 2026, 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

31 juil. 2026, 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30 juil. 2026, 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29 juil. 2026, 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

28 juil. 2026, 18:02 UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

27 juil. 2026, 17:36 UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

23 juil. 2026, 00:01 UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

22 juil. 2026, 22:01 UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

21 juil. 2026, 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20 juil. 2026, 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

-1.67% baisse

Prévisions sur 12 Mois

Moyen 230.2 USD -1.67%

Haut 265 USD

Bas 213 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

14 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.